Tech Transfer Central

Getting to a License: Valuation and Strategic Marketing of Biotech, Therapeutics and other Life Science IP Assets

Format: On-Demand Video/Transcript, or DVD
Originally presented: Thursday, May 12, 2016
Price: $197
order button view cart

Valuation is a confusing and often contested topic among life sciences and tech transfer professionals. With so many different valuation approaches, it sometimes seems nearly impossible to get realistic and objective figures that all parties can agree on.

However, companies in the life sciences industry require accurate valuations in order to raise investment funds, license IP, and set development milestones. There are a few valuation methods that the industry traditionally relies upon, but they are not only confusing but also time consuming to evaluate.

That’s why Technology Transfer Tactics has invited a team of experts to lead this enlightening webinar that will offer an easy-to-apply yet sophisticated model to accurately value your biotech, pharma, medical device and therapeutic IP while identifying market potential, potential licensees, and development partners. Please join Dr. S. Michael Camp, Founder and Executive Director of the Technology Entrepreneurship and Commercialization (TEC) Institute at The Ohio State University, and Justin A. Miller, MBA, founder and chief business officer of Quorum Therapeutics, when they team up to present this one-hour webinar:

Getting to a License: Valuation and Strategic Marketing of Biotech, Therapeutics and other Life Science IP Assets

In this practical program, you’ll get a detailed blueprint for valuing life sciences assets that takes into account the needs and requirements of both industry partners and the university. Here’s a brief look at the agenda: 

  • Financial valuation of early-stage therapeutics by focusing on:
    • Underlying economics of drug development
    • Peak market potential assessment
    • Sales and royalty revenue forecasting
    • Design and impact of milestone payments
    • Probability-adjusted net present value (eNPV)
    • Sensitivity analysis
    • Effect of IP lifespan
  • Selecting and prioritizing lead indication or go-to-market strategy for IP
  • Effect of future FDA designations such as Orphan, Fast Track and QIDP
  • Understanding development economics and timelines of licensees
  • Prioritizing patent and IP portfolio geographic coverages
  • Identifying and communicating the value of IP to licensees
  • Real world cases and their outcomes

Your Program Faculty

S. Michael CampDr. S. Michael Camp is an entrepreneur, educator, and senior business consultant with more than 25 years of experience in architecting innovative models for the rapid monetization and commercialization of technology – including the design and launch of new ventures – and designing and administering hybrid, interdisciplinary educational programs in entrepreneurship. He is currently the Founder and Executive Director of the Technology Entrepreneurship and Commercialization (TEC) Institute at The Ohio State University. For the TEC Institute, Dr. Camp is the chief architect of numerous proprietary technology evaluation protocols and IP marketing and monetization services. Since 2007, under his leadership, the TEC Institute has trained nearly 650 interdisciplinary graduate students in the art and science of technology commercialization and reviewed the commercial potential of more than 400 scientific discoveries. He has developed numerous courses and assisted in the design of award-winning undergraduate and graduate level academic programs in entrepreneurship. As Vice President at the Ewing Kauffman Foundation, Dr. Camp was responsible for the $4+ million applied entrepreneurship research program and led partnerships with many of the world’s leading academic institutions in designing and implementing comprehensive scientific research and educational programs. Dr. Camp is currently the Founder and Principal of Prophetech Global IP Solutions, which provides strategic decision support regarding speed to monetization and risk mitigation in the commercialization of innovative technologies across multiple industries.

Justin A. MillerJustin A. Miller, MBA is a pharmaceutical entrepreneur and life science business development consultant. As Founder and Chief Business Officer of Quorum Therapeutics, a preclinical pharmaceutical firm developing novel therapeutics for serious bacterial infections, and as Principal of his own consulting firm, Justin has extensive experience in the commercialization, monetization and valuation of life science technologies. Previously, he served as Senior Manager of Strategic Marketing and Business Development at Kinnear Pharmaceuticals, a private equity backed preclinical biotechnology firm. Furthermore, as the Senior Life Science Strategy Consultant at The Ohio State University, he advised the Technology Commercialization Office on numerous licensing transactions.

Our Guarantee of Quality and Value

We stand 100% behind the quality and value of our products. If you are dissatisfied, simply let us know and we will send you an immediate refund for your entire order -- no questions asked.

order button
view cart

Click here for a printable order form